{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT04928807","nct_id":"NCT04928807","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04928807. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Radiotherapy will employ conformal or intensity-modulated radiation therapy, with a pelvic irradiation dose of 25 Gy/5 Fractions/1 week. Then rest for 1 week after radiotherapy and begin to receive neoadjuvant chemotherapy CAPOX and camrelizumab, for 2 cycles.\n\nThe patients were operated within 10 weeks after the last radiotherapy, and the surgical method is total mesorectal excision.\n\nPostoperative adjuvant therapy will be started 4-6 weeks after surgery, and the adjuvant regimen was the same as that before operation (CAPOX + camrelizumab) for 6 cycles","label":"Short course radiotherapy sequential camrelizumab and chemotherapy","type":"EXPERIMENTAL"},{"description":"The patients received neoadjuvant therapy of CAPOX 2 weeks after long-term concurrent chemoradiotherapy (28\\*1.8Gy, during the same period, capecitabine was 825 mg / m2, twice a day, 5 days a week).\n\nThe patients were operated within 10 weeks after the last radiotherapy. Adjuvant therapy should begin within 4-6 weeks after surgery, and the adjuvant regimen was the same as that before operation (CAPOX) for 6 cycles","label":"Long term concurrent chemoradiotherapy and sequential chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Jiangsu HengRui Medicine Co., Ltd."],"completion_date":{"date":"2028-03-20","type":"ESTIMATED"},"conditions":["Rectal Cancer"],"enrollment":{"count":231,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Short course radiotherapy sequential camrelizumab and chemotherapy","otherNames":[],"type":"COMBINATION_PRODUCT"}],"last_update":"2026-02-27","lead_sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","official_title":"A Multicenter, Randomized, Open-label, Controlled Phase III Clinical Trial of Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in the Treatment for Locally Advanced Rectal Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-03-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"pathological complete response (pCR) rate","timeFrame":"an expected average of 5 months"}],"references":[{"citation":"You Q, Jin M, Zhou B, Huang C, Lin Z, Hu J, Xue J, Chen X, Xiao Y, Li R, Zong Y, Wu M, Zhang T, Liu H. Gut microbiome components predict response to neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): a prospective study. Front Pharmacol. 2026 May 29;17:1829108. doi: 10.3389/fphar.2026.1829108. eCollection 2026.","pmid":"42292847","type":"DERIVED"},{"citation":"Zhang F, Yu D, Yang J, Zhai M, Li L, Zhao L, Wang J, Zhang T, Lin Z. Pretreatment high cholesterol and low neutrophils predict complete pathological response after neoadjuvant short-course radiotherapy followed by chemotherapy and immunotherapy in locally advanced rectal cancer. Oncol Lett. 2023 Jun 7;26(1):319. doi: 10.3892/ol.2023.13905. eCollection 2023 Jul.","pmid":"37332340","type":"DERIVED"}],"start_date":{"date":"2021-07-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)","url":"https://clinicaltrials.gov/study/NCT04928807"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04928807"}